Opinion statement Second malignancies are a rare but well-defined late complication after
autologous and allogeneic hematopoietic stem-cell transplantation (SCT). Solid …

Despite excellent cure rates with modern front-line regimens, up to 20% of patients with
Hodgkin lymphoma will progress through front-line therapy or experience disease relapse …

Therapy-related myeloid neoplasms (tMNs) are severe adverse events that can occur after
treatment with autologous hematopoietic stem cell transplantation (ASCT). This study aimed …

Therapy-related myeloid neoplasm (t-MN) is a threatening complication of autologous stem
cell transplantation (ASCT). Detecting clonal hematopoiesis (CH) mutations in …

Autologous stem cell transplantation (ASCT) remains a key therapeutic strategy for treating
patients with relapsed or refractory non‐Hodgkin and Hodgkin lymphoma. Clonal …

The occurrence of secondary hypogammaglobulinemia (SH) after chemo-immunotherapy
represents a potential side effect in patients with indolent non-Hodgkin lymphomas (iNHL) …

Therapy-related myeloid neoplasm (t-MN) is a rare but devastating consequence of
chemotherapy and/or radiotherapy used for the treatment of solid cancers and various …

As hematopoietic cell transplantation (HCT) and cellular therapy expand to new indications
and international access improves, the number of HCTs performed annually continues to …

Background With the improving outcomes of patients with follicular lymphoma (FL), it is
imperative to focus on survivorship issues, including the development of second primary …

Background Understanding the mortality patterns of patients with lymphoma and myeloma,
who have undergone autologous hematopoietic stem cell transplantation (ASCT) might …